Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic

Meera V Ragavan; Nichole Legaspi; Alyssa LaLanne; Julian C Hong; Eric J Small; Hala T Borno

doi:10.1001/jamaoncol.2022.4919

Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic

JAMA Oncol. 2022 Dec 1;8(12):1849-1851. doi: 10.1001/jamaoncol.2022.4919.

Authors

Meera V Ragavan¹, Nichole Legaspi¹, Alyssa LaLanne², Julian C Hong^{2

3

4}, Eric J Small^{1

2}, Hala T Borno^{1

5}

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco.
² Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco.
³ Department of Radiation Oncology, University of California, San Francisco, San Francisco.
⁴ Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco.
⁵ Trial Library, San Francisco, California.

No abstract available

Plain language summary

This cross-sectional study assesses whether a change occurred in reporting of serious adverse events for patients in oncology clinical trials in the US during the COVID-19 pandemic.

Publication types

Letter

MeSH terms

Adverse Drug Reaction Reporting Systems
COVID-19*
Clinical Trials as Topic
Humans
Neoplasms* / drug therapy
Pandemics
Research Report